Janumet Indications/Uses

SITAGLIPTIN + METFORMIN HCl (JANUMET) is indicated as initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control.
SITAGLIPTIN + METFORMIN HCl (JANUMET) is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.
SITAGLIPTIN + METFORMIN HCl (JANUMET) is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: Metformin, sitagliptin, or a sulfonylurea.
SITAGLIPTIN + METFORMIN HCl (JANUMET) is indicated as part of triple combination therapy with a PPARγ agonist (i.e., thiazolidinediones) as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin, or a PPARγ agonist.
SITAGLIPTIN + METFORMIN HCl (JANUMET) is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in combination with insulin.